Funda DİNC ELİBOL, Sezen Bozkurt KOSEOGLU

Does bone mineral density change in polycystic ovarian syndrome?

Polycystic ovarian syndrome (PCOS), is the most frequent endocrine disorder in reproductive age and PCOS has effects on bone metabolism. There is conflicting data on the effect of PCOS on bone metabolism. The aim of this study to evaluate whether bone mineral density (BMD) changes in PCOS or not. Twenty-seven patients with PCOS for the study group and 27 patients for the control group were included in this retrospective study. BMD measurements with abdomen CTs were taken for each lumbar vertebra (from vertebra L1 to vertebra L5) and sacral 1st vertebra. BMD measurements were recorded as HU. The lumbar 5th vertebra’s BMD was 238.70±47.80 HU in the PCOS group and 264.91±36.62 in the control group and the difference was statistically significant (P=0.033). BMD values of all vertebras were lower in the PCOS group than the control group, but statistically, significance was seen in only the lumbar 5th vertebra. BMD values were found to be lower in PCOS than the control group for all vertebras in this study. Even though there is no scanning method recommend to women in PCOS for BMD according to the current guidelines and literature, we think these patients should be evaluated more carefully in advanced ages in the light of the results of our study.

PDF

___

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.

Bozkurt Koseoglu S, Dinc Elibol F. Does the Pituitary Gland Volume Change in Polycystic Ovary Syndrome? Gynecol Obstet Invest. 2018;83:515–9.

Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:281–96.

Karadağ C, Yoldemir T, Gogas Yavuz D. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecol Endocrinol. 2017;33:234–7.

Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005;353:164–71.

Celi M, Rao C, Scialdoni A et al. Bone mineral density evaluation in osteoporosis: why yes and why not? Aging Clin Exp Res. 2013;25:47-9.

Schreiber JJ, Anderson PA, Hsu WK. Use of computed tomography for assessing bone mineral density. Neurosurg Focus. 2014;37:4.

Smith A, Khan M, Varney E et al. Opportunistic bone density screening for the abdominal radiologist using colored CT images: a pilot retrospective study. Abdom Radiol. 2019;44:775–82.

Zou D, Li W, Deng C, Du G, Xu N. The use of CT Hounsfield unit values to identify the undiagnosed spinal osteoporosis in patients with lumbar degenerative diseases. Eur Spine J. 2018:1–9.

10. Pickhardt PJ, Pooler BD, Lauder T et al. Opportunistic Screening for Osteoporosis Using Abdominal Computed Tomography Scans Obtained for Other Indications. Ann Intern Med. 2013;158:588.

11. Gausden EB, Nwachukwu BU, Schreiber JJ, Lorich DG, Lane JM. Opportunistic Use of CT Imaging for Osteoporosis Screening and Bone Density Assessment. J Bone Jt Surg. 2017; 99: 1580–90.

12. Khosla S, Riggs BL, Robb RA et al. Relationship of Volumetric Bone Density and Structural Parameters at Different Skeletal Sites to Sex Steroid Levels in Women. J Clin Endocrinol Metab. 2005; 90: 5096–103.

13. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and Bone. Endocr Rev. 2004; 25: 389–425.

14. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril. 1999; 72: 21–5.

15. Di Carlo C, Shoham Z, MacDougall J et al. Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea. Fertil Steril. 1992;57:314–9.

16. To WW, Wong MW. A comparison of bone mineral density in normal weight and obese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2012;25:248–53.

17. Adami S, Zamberlan N, Castello R et al. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf). 1998;48:169–73.

18. Ganie M, Chakraborty S, Sehgal A et al. Bone Mineral Density is Unaltered in Women with Polycystic Ovary Syndrome. Horm Metab Res. 2018;50:75460.

19. Schmidt J, Dahlgren E, Brännström M, Landin-Wilhelmsen K. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study. Clin Endocrinol (Oxf). 2012;77:207–14.

20. Alacreu E, Moratal D, Arana E. Opportunistic screening for osteoporosis by routine CT in Southern Europe. Osteoporos Int. 2017;28:983–90.

21. Li Y-L, Wong K-H, Law MW-M et al. Opportunistic screening for osteoporosis in abdominal computed tomography for Chinese population. Arch Osteoporos. 2018;13:76.

22. Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA. Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol. 2009;161:583–9.

23. Yüksel O, Dökmetaş HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab. 2001;19:257–62.

24. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018;17:27785.

25. Katulski K, Slawek S, Czyzyk A, Podfigurna-Stopa A, Paczkowska K, Ignaszak N, et al. Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest. 2014;37:1219–24.